Spotlight on Science Meetings, Conferences and Events brings you information on the following event: FASEB 2017 SRC Hematologic Malignancies
This SRC focuses on bringing together biochemists, geneticists, molecular biologists and clinicians interested in the pathophysiology of the leukemias and lymphomas, and the development of novel therapies for these diseases. Leukemia and lymphoma has provided a number of key paradigms for molecularly targeted cancer therapy, as illustrated by the remarkable success of all-trans-retinoic acid for the treatment of acute promyelocytic leukemia and tyrosine kinase inhibitor therapy for chronic myelogenous leukemia. New and promising small-molecule compounds and antibodies targeting epigenetic regulators, surface receptors and downstream signaling pathways are currently under development and will be discussed at this meeting. Added to these examples of targeted therapy, immunotherapy, including checkpoint inhibition and modified T cell-based therapies have emerged as important future anti-leukemia/lymphoma treatments.
The meeting will cover a broad range of topics, including hematopoietic stem cell differentiation, identification and study of novel oncogenes and tumor suppressors, mechanisms of action of products of chromosomal translocations, normal and pathologic signaling in hematopoietic cells, aberrant epigenetic/transcriptional control, genomics of hematological malignancies, the role of tumor microenvironment, and the development of new experimental models of hematologic malignancies.
Highlights
• Career Development Sessions
• Meet the Expert sessions
• Short talks selected from submitted abstracts
Keynote Speakers
• Jay Bradner
• Novartis
